GNBT.OB

[stocks2watch2]

Generex Biotechnology to Present Pandemic Influenza Vaccine Program at Bird Flu Summit in Washington, D.C.
Synthetic Peptide Vaccine for Avian Influenza Provides H5N1 Specific T Helper Stimulation
E-mail | Print |  | Disable live quotes Last Update: 9:00 AM ET Feb 27, 2006


TORONTO, Feb 27, 2006 (MARKET WIRE via COMTEX) -- Generex Biotechnology Corporation (GNBT : generex biotechnology cp del com
News , chart, profile, more
Last: 2.22+0.35+18.72%

8:48am 02/27/2006

GNBT2.22, +0.35, +18.7%) announced today that Dr. Douglas Powell, Ph.D., Director of Immunobiology of Antigen Express, Inc., the Company's wholly owned subsidiary, will make a presentation at an international conference on the Antigen Express program for the development of a novel synthetic peptide vaccine designed to protect against the potentially pandemic avian influenza virus.
The international Bird Flu Summit will take place in Washington, D.C. from February 27 - 28, 2006. The purpose of the summit is to bring greater transparency to the global effort to fight the flu, provide an exchange network among the summit participants, and improve the quality of communication, coordination, and collaboration needed for an international response program. Facilities will be available for sponsorship, exhibition, media interviews, and contract conferences.
The vaccine design strategy being developed by Antigen Express employs small portions of a protein from the pathogenic agent, in this case portions of the H5 protein, and modifying them for maximal stimulation of the immune systems' T helper cells. These cells play a critical role in directing a variety of immune responses against pathogenic agents as well as in preserving immunological memory. The advantage of using small fragments of proteins is that they can be manufactured by synthetic means in existing facilities. This means that very large amounts of the vaccine can be made relatively rapidly and at lower cost. Currently, neither the traditional egg-based method nor the cell culture based method for production of H5N1 vaccines can supply quantities sufficient for vaccinating more than a fraction of the U.S. population because of limitations on manufacturing capacity.
Antigen Express has pioneered the development of antigen-specific peptide vaccines for stimulation of T helper cells. The work of the founder of Antigen Express, Dr. Robert Humphreys, showed how the activity of antigenic peptides could be greatly enhanced by addition of a small portion of the MHC class II associated Ii protein (termed Ii-Key). This increased potential for antigen-specific T helper stimulation has been demonstrated in a variety of cell culture systems as well as animal models. Interim results from an ongoing clinical trial of an Ii-Key-modified peptide vaccine from Antigen Express designed for HER-2/neu positive cancers are encouraging. That peptide, though derived form the HER-2/neu protein, was designed by methods similar to those being used with portions of the H5 protein.
"We are very pleased with the progress that has been made at Antigen Express in developing a synthetic vaccine to combat avian influenza," said Anna Gluskin, President and Chief Executive Officer of Generex. "There is clearly an urgent need for this type of vaccine and we are advancing it to the clinic as rapidly as possible."

[stocks2watch2]

Price 2.49
Broke through 2.42 resistance, next resistance 2.61.
Symbol: GNBT

[ INTC, AMAT, GNBT ] Nasdaq most active stocks: INTC AMAT GNBT CSCO MSFT
By  MarketWatch
2/27/2006 10:13:30 AM

[stocks2watch2]

Sold 2000 @ 2.60,holding 32000 @ .32.

[catrader]

Sold 2000 @ 2.60,holding 32000 @ .32.

when did you buy at 0.32, back in 2003?  Last 52 weeks never been that cheap.  Well like you, hope it continues runup.

[stocks2watch2]

Sold 2000 @ 2.60,holding 32000 @ .32.

when did you buy at 0.32, back in 2003?  Last 52 weeks never been that cheap.  Well like you, hope it continues runup.

Never said I bought @ .32, go back and read my posts in this thread. I have been averaging down from 48900 shares. I am now holding 32000 @ an averaged down price of .32.I bought @ .81 and .82 Good Luck with your trades.

[dennis67]

well i sold half at 2.50 and watchd it go up more  now its back down i feal better about not loosing as much now if it drops.stocks2watch you seem to sel a lot do you always do this or just when you  have  lots of shares. i am so use to seing the liars on yahoo saying they  have  50k of this and 50k of that and i no its not true  i meen no dissrespect to you or anyone here  but do  you realy  buy as much stocks as you post on. i am triying to learn all i can

[GatewayStocks]

Blasting off and this is just the start...JMHO and GLTA

[davidzwq]

Bad news for GNBT...

http://knobias.10kwizard.com/filing.php?repo=tenk&ipage=3995508&doc=1&total=&bac

[GatewayStocks]

 
Form 8-K for GENEREX BIOTECHNOLOGY CORP


--------------------------------------------------------------------------------

28-Feb-2006

Material Modifications, Financial Statements and Exhibits



Item 3.03 Material Modification to Rights of Security Holders.
On February 27, 2006, Generex Biotechnology Corporation (the Company) and four of its investors, Iroquios Capital LP (Iroquois), Cranshire Capital, L.P. (Cranshire), Smithfield Fiduciary LLC (Smithfield) and Omicron Master Trust
(Omicron and together with Iroquois, Cranshire and Smithfield, the Investors)
amended the terms of outstanding warrants to purchase common stock (Warrants) to accelerate their exercise date to February 27, 2006. These Warrants consist of Warrants issued (i) to Omicron on July 22, 2005 for 243,902 shares of the Companys common stock at $0.82 per share and currently exercisable; (ii) to Cranshire on October 20, 2005 for 300,000 shares of the Companys common stock at $1.20 per share and originally exercisable on April 20, 2006; (iii) to Iroquois on October 20, 2005 for 609,756 shares of the Companys common stock at $1.20 per share and originally exercisable on April 20, 2006; (iv) to Cranshire on October 27, 2005 for 309,756 shares of the Companys common stock at $1.25 per share and originally exercisable on April 27, 2006; (v) to Omicron and Smithfield on October 27, 2006 for 609,756 shares each of the Companys common stock at $1.25 per share and originally exercisable on April 27, 2006; (vi) to each of the Investors on October 27, 2005 for 304,878 shares each of the Companys common stock at $1.25 per share and originally exercisable on April 27, 2006; (vii) to Cranshire on December 9, 2005 for 1,829,268 shares of the Companys common stock at $1.25 per share and originally exercisable on June 9, 2006; and (viii) to each of the Investors on January 20, 2006 for 952,381 shares each of the Companys common stock at $1.05 per share and originally exercisable on July 20, 2006.

The Investors agreed to immediately exercise 100% of these Warrants (for aggregate gross proceeds to the Company of $11,014,267) in exchange for (a) the acceleration of the exercise periods and (b) the issuance of additional warrants equal to 50% of the exercised Warrants (an aggregate of 4,770,617 shares). The new warrants will have an exercise price of $3.00 per share and will be exercisable for five years commencing on August 27, 2006.

The offer and sale of the warrants to the Investors, including the shares of common stock into which such warrants are exercisable, are exempt from registration under the Securities Act of 1933, as amended (Securities Act), in reliance upon Section 4(2) thereof. Each of the Investors has previously represented and warranted to the Company that it is an accredited investor as that term is defined in Rule 501(a) of Regulation D promulgated under the Securities Act. The certificates representing such warrants and shares of common stock issued upon exercise of such warrants will be legended to indicate that they are restricted. The sale of such securities did not involve the use of underwriters, and no commissions were paid in connection therewith.

[GatewayStocks]

 
Form 8-K for GENEREX BIOTECHNOLOGY CORP


--------------------------------------------------------------------------------

28-Feb-2006

Material Modifications, Financial Statements and Exhibits



Item 3.03 Material Modification to Rights of Security Holders.
On February 27, 2006, Generex Biotechnology Corporation (the Company) and four of its investors, Iroquios Capital LP (Iroquois), Cranshire Capital, L.P. (Cranshire), Smithfield Fiduciary LLC (Smithfield) and Omicron Master Trust
(Omicron and together with Iroquois, Cranshire and Smithfield, the Investors)
amended the terms of outstanding warrants to purchase common stock (Warrants) to accelerate their exercise date to February 27, 2006. These Warrants consist of Warrants issued (i) to Omicron on July 22, 2005 for 243,902 shares of the Companys common stock at $0.82 per share and currently exercisable; (ii) to Cranshire on October 20, 2005 for 300,000 shares of the Companys common stock at $1.20 per share and originally exercisable on April 20, 2006; (iii) to Iroquois on October 20, 2005 for 609,756 shares of the Companys common stock at $1.20 per share and originally exercisable on April 20, 2006; (iv) to Cranshire on October 27, 2005 for 309,756 shares of the Companys common stock at $1.25 per share and originally exercisable on April 27, 2006; (v) to Omicron and Smithfield on October 27, 2006 for 609,756 shares each of the Companys common stock at $1.25 per share and originally exercisable on April 27, 2006; (vi) to each of the Investors on October 27, 2005 for 304,878 shares each of the Companys common stock at $1.25 per share and originally exercisable on April 27, 2006; (vii) to Cranshire on December 9, 2005 for 1,829,268 shares of the Companys common stock at $1.25 per share and originally exercisable on June 9, 2006; and (viii) to each of the Investors on January 20, 2006 for 952,381 shares each of the Companys common stock at $1.05 per share and originally exercisable on July 20, 2006.

The Investors agreed to immediately exercise 100% of these Warrants (for aggregate gross proceeds to the Company of $11,014,267) in exchange for (a) the acceleration of the exercise periods and (b) the issuance of additional warrants equal to 50% of the exercised Warrants (an aggregate of 4,770,617 shares). The new warrants will have an exercise price of $3.00 per share and will be exercisable for five years commencing on August 27, 2006.

The offer and sale of the warrants to the Investors, including the shares of common stock into which such warrants are exercisable, are exempt from registration under the Securities Act of 1933, as amended (Securities Act), in reliance upon Section 4(2) thereof. Each of the Investors has previously represented and warranted to the Company that it is an accredited investor as that term is defined in Rule 501(a) of Regulation D promulgated under the Securities Act. The certificates representing such warrants and shares of common stock issued upon exercise of such warrants will be legended to indicate that they are restricted. The sale of such securities did not involve the use of underwriters, and no commissions were paid in connection therewith.

[GatewayStocks]

Iroquois and these other are all into toxic financing...sorry for the stock especially mid-long term... it will get some bird flu play though

[stocks2watch2]

Generex Biotechnology Receives $11 Million From Warrant Exercises
Company Now Has in Excess of $31 Million in Cash-on-Hand
E-mail | Print |  | Disable live quotes Last Update: 8:59 AM ET Feb 28, 2006


TORONTO, Feb 28, 2006 (MARKET WIRE via COMTEX) -- Generex Biotechnology Corporation (GNBT : generex biotechnology cp del com
News , chart, profile, more
Last: 2.38+0.16+7.21%

8:47am 02/28/2006
Add to portfolio
Analyst
Create alertInsider
Discuss
Financials
Sponsored by:
GNBT2.38, +0.16, +7.2%) announced today that it has received an aggregate of $11 million as a result of the exercise by existing Company investors of previously issued warrants. The receipt of these funds has put the Company's cash-on-hand at more than $31 million, its strongest cash position in more than four years.
"We are very pleased to have achieved such a strong cash position," said Anna Gluskin, the Company's President & Chief Executive Officer. "The availability of such significant funding puts us in a very good position to continue our global endeavors to commercialize Generex Oral-lyn(TM), our proprietary oral insulin product, and the work of our Antigen Express subsidiary on its proprietary novel synthetic peptide vaccine programs for avian influenza and breast cancer."

[stocks2watch2]

Dennis    and Catrader I got your messages sorry I don't have time to reply now. My plan is to make 16 sells of 2000 on my remaining shares, I'm selling into each upturn.I just sold 2000 @ 2.34.

[setravis]

Technicals
Most Actives

Last Price Quote is:
24.77%above 13-day EMA
69.13%above 50-day EMA
RS Rating: 99 

Fundamentals
Key Data:
Market Cap (M): $141.04 
P/E Ratio: NA 
PEG Ratio: N/A 
Next Earnings: N/A
Last Analyst Rating: Buy

Volume: 9,310,655
Avg Vol (3m): 5,323,810


The Chart.....

[stocks2watch2]

We are due for a pr. We should see an update on the recent meetings soon.If we get something positive we might see a run into the 3's if not we'll probally drift down to around low 2's, support is 2.12. Catrader I do know a lot about the company, but don't know for sure where the pps is going. There are a lot of things going on with GNBT right now, and as they just said they are in there strongest cash position in 4 years. I am in contact with Rose C. Perri Chief Financial Officer, COO, Treasurer, Sec., Director, as she emails me copies of released pr's. Catrader and Dennis I always try to sell a part of my position asap to average down, when I have a larger position I will make several sells. Yes it would be nice to know your @ the top and sell it all , but it never works that way.Dennis my trading portfolio is well into the 6 digits is why I buy as often as I do. This is not the first time I have been called out. I will show you my 30k on inet @ 9:00 am for 2.51 and remove them @ 9:15.Please do not buy just because I post on a stock, no one is always right in the markets. I can not tell you when to buy and sell. I wish both of you the best of luck in the markets.